A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin

Trial Profile

A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs TTP 399 (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms AGATA
  • Sponsors vTv Therapeutics LLC.
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 May 2017 Results presented at the ENDO 2017 Annual Meeting, according to a vTv Therapeutics media release.
    • 27 Feb 2017 According to a vTv Therapeutics media release, a manuscript with data from the study is in preparation and will be submitted for publication during the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top